Publications

How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System
Danuglipron

Type 2 diabetes mellitus (T2DM) is one of the most diagnosed …

A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)‐Lowering Agent

Patients with genetically associated elevated lipoprotein(a) …

Abelacimab

Thromboembolic disorders are a major cause of morbidity and …

Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System WIth Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes
A Critical Review of the Efficacy and Safety of Inclisiran
A Review on the Efficacy and Safety of Oral Semaglutide
A prospective, multicenter, international study to explore the effect of three different amplitude settings in female subjects with urinary urge incontinence receiving interstim therapy
Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia
Tirzepatide: Summary of the Emerging Data on the Novel GLP-1/GIP Dual Agonist
Praliciguat
Efpeglenatide
Filipino-American Lipid Trial
Aliskiren and valsartan combination therapy for the management of hypertension
Carvedilol Reduces Aortic Wave Reflection and Improves Left Ventricular⁄Vascular Coupling: A Comparison With Atenolol
Newer Agents for the Management of Overactive Bladder
Obesity and the Risk of Heart Failure
Less RAAS is more, or not
Mycobacterium tuberculosis H37Rv: In Silico Drug Targets Identification by Metabolic Pathways Analysis
Selective detection of Mg2+ ions via enhanced fluorescence emission using Au–DNA nanocomposites
Management of hypertension with fixed-dose triple-combination treatments
SGLT-2 inhibitors and their potential in the treatment of diabetes
Tofogliflozin: A Highly Selective SGLT2 Inhibitor For Treatment Of Type 2 Diabetes
Advances in Myocardial Infarction Managment

https://www.futuremedicine.com/doi/abs/10.2217/ebo.12.428

Baseline predictors of central aortic blood pressure: A PEAR substudy